{"altmetric_id":2453909,"counts":{"readers":{"mendeley":54,"citeulike":0,"connotea":0},"blogs":{"unique_users_count":1,"unique_users":[53757],"posts_count":1},"total":{"posts_count":8},"reddit":{"unique_users_count":1,"unique_users":["isosafrole"],"posts_count":1},"twitter":{"unique_users_count":3,"unique_users":["SleepResearch_","genomecenter","bionavist"],"posts_count":5},"wikipedia":{"unique_users_count":1,"unique_users":["en:4497996"],"posts_count":1}},"selected_quotes":["True or false? cause(#Disorder, #Ube3aSystemExpressionLoss) #IntellectualDisability","True or false? cause(#Disorder, #GeneSystemExpressionLoss) #IntellectualDisability","True or false? encode(#Disorder, #Ligase) #IntellectualDisability"],"citation":{"abstract":"Angelman syndrome is a monogenic neurologic disorder that affects 1 in 15,000 children, and is characterized by ataxia, intellectual disability, speech impairment, sleep disorders, and seizures. The disorder is caused by loss of central nervous system expression of UBE3A, a gene encoding a ubiquitin ligase. Current treatments focus on the management of symptoms, as there have not been therapies to treat the underlying molecular cause of the disease. However, this outlook is evolving with advances in molecular therapies, including artificial transcription factors a class of engineered DNA-binding proteins that have the potential to target a specific site in the genome.","abstract_source":"pubmed","altmetric_jid":"4f6fa4d03cf058f6100007cd","authors":["Barbara J Bailus","David J Segal"],"doi":"10.1186\/1471-2202-15-76","first_seen_on":"2014-06-20T22:14:33+00:00","issns":["1471-2202",""],"issue":"1","journal":"BMC Neuroscience","last_mentioned_on":1461808722,"links":["http:\/\/www.biomedcentral.com\/content\/pdf\/1471-2202-15-76.pdf","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24946931?dopt=Abstract","http:\/\/www.biomedcentral.com\/1471-2202\/15\/76","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24946931","http:\/\/dx.doi.org\/10.1186\/1471-2202-15-76","http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4069279"],"pdf_url":"http:\/\/www.biomedcentral.com\/content\/pdf\/1471-2202-15-76.pdf","pmid":"24946931","pubdate":"2014-06-19T00:00:00+00:00","publisher":"BioMed Central Ltd","publisher_subjects":[{"name":"Neurosciences","scheme":"era"},{"name":"Cognitive Science","scheme":"era"},{"name":"Biochemistry And Cell Biology","scheme":"era"}],"scopus_subjects":["Life Sciences","Neuroscience"],"startpage":"76","subjects":["neurology"],"title":"The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders","type":"article","volume":"15","mendeley_url":"http:\/\/www.mendeley.com\/research\/prospect-molecular-therapy-angelman-syndrome-other-monogenic-neurologic-disorders"},"altmetric_score":{"score":11.75,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":11.75},"context_for_score":{"all":{"total_number_of_other_articles":7621460,"mean":6.5607387299425,"rank":626152,"this_scored_higher_than_pct":91,"this_scored_higher_than":6992384,"rank_type":"exact","sample_size":7621460,"percentile":91},"similar_age_3m":{"total_number_of_other_articles":175692,"mean":7.2428688549786,"rank":17375,"this_scored_higher_than_pct":90,"this_scored_higher_than":158207,"rank_type":"exact","sample_size":175692,"percentile":90},"this_journal":{"total_number_of_other_articles":805,"mean":3.412039800995,"rank":43,"this_scored_higher_than_pct":94,"this_scored_higher_than":760,"rank_type":"exact","sample_size":805,"percentile":94},"similar_age_this_journal_3m":{"total_number_of_other_articles":33,"mean":2.843125,"rank":2,"this_scored_higher_than_pct":93,"this_scored_higher_than":31,"rank_type":"exact","sample_size":33,"percentile":93}}},"demographics":{"poster_types":{"member_of_the_public":2,"researcher":1},"users":{"twitter":{"cohorts":{"Members of the public":2,"Scientists":1}},"mendeley":{"by_status":{"Unspecified":3,"Professor > Associate Professor":4,"Researcher":10,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":8,"Student  > Postgraduate":3,"Student  > Master":8,"Other":4,"Student  > Bachelor":12},"by_discipline":{"Materials Science":1,"Medicine and Dentistry":11,"Social Sciences":1,"Psychology":3,"Unspecified":3,"Environmental Science":1,"Arts and Humanities":1,"Design":1,"Neuroscience":4,"Earth and Planetary Sciences":1,"Immunology and Microbiology":2,"Agricultural and Biological Sciences":18,"Computer Science":1,"Biochemistry, Genetics and Molecular Biology":6}}},"geo":{"twitter":{"US":2},"mendeley":{"NL":1}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/SleepResearch_\/status\/505302312672587776","license":"datasift","citation_ids":[2453909],"posted_on":"2014-08-29T10:33:54+00:00","author":{"name":"Sleep Research","url":"http:\/\/www.facebook.com\/pages\/Sleep-Research\/105093012946768?ref=hl","image":"https:\/\/pbs.twimg.com\/profile_images\/2694954403\/9f320ff3ac0d13ed3582e204a8c1c768_normal.jpeg","description":"Highlights and news from the latest research on sleep","id_on_source":"SleepResearch_","tweeter_id":"868205960","geo":{"lt":null,"ln":null},"followers":1590},"tweet_id":"505302312672587776"},{"url":"https:\/\/twitter.com\/genomecenter\/status\/480111375273181184","license":"datasift","citation_ids":[2453909],"posted_on":"2014-06-20T22:14:06+00:00","author":{"name":"The Genome Center","url":"http:\/\/genomecenter.ucdavis.edu","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000708374350\/4bf3cec691b4a9814e5f812c0e0ecf78_normal.png","description":"The UC Davis Genome Center is home to a diverse range of cutting-edge genomics research and provides world-class training courses in bioinformatics.","id_on_source":"genomecenter","tweeter_id":"2180508037","geo":{"lt":38.54491,"ln":-121.74052,"country":"US"},"followers":694},"tweet_id":"480111375273181184"},{"url":"https:\/\/twitter.com\/bionavist\/status\/543752297746939904","license":"datasift","citation_ids":[2453909],"posted_on":"2014-12-13T13:00:24+00:00","author":{"name":"Berkeley Bot","url":"http:\/\/markfarrell.ca\/creal","image":"http:\/\/pbs.twimg.com\/profile_images\/530906132680695808\/WJYpLqU8_normal.png","description":"Beep! Boop! Bop! I am Berkeley Bot.","id_on_source":"bionavist","tweeter_id":"2866388393","geo":{"lt":"37.8708789","ln":"-122.2728247","country":"US"},"followers":0},"tweet_id":"543752297746939904"},{"url":"https:\/\/twitter.com\/bionavist\/status\/543752296543178753","license":"datasift","citation_ids":[2453909],"posted_on":"2014-12-13T13:00:24+00:00","author":{"name":"Berkeley Bot","url":"http:\/\/markfarrell.ca\/creal","image":"http:\/\/pbs.twimg.com\/profile_images\/530906132680695808\/WJYpLqU8_normal.png","description":"Beep! Boop! Bop! I am Berkeley Bot.","id_on_source":"bionavist","tweeter_id":"2866388393","geo":{"lt":"37.8708789","ln":"-122.2728247","country":"US"},"followers":0},"tweet_id":"543752296543178753"},{"url":"https:\/\/twitter.com\/bionavist\/status\/543752295272288256","license":"datasift","citation_ids":[2453909],"posted_on":"2014-12-13T13:00:24+00:00","author":{"name":"Berkeley Bot","url":"http:\/\/markfarrell.ca\/creal","image":"http:\/\/pbs.twimg.com\/profile_images\/530906132680695808\/WJYpLqU8_normal.png","description":"Beep! Boop! Bop! I am Berkeley Bot.","id_on_source":"bionavist","tweeter_id":"2866388393","geo":{"lt":"37.8708789","ln":"-122.2728247","country":"US"},"followers":0},"tweet_id":"543752295272288256"}],"reddit":[{"title":"The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders [BMC Neurosci., June 2014 \u2014 free full-text]","url":"http:\/\/www.reddit.com\/r\/pharmacology\/comments\/2ewpsw\/the_prospect_of_molecular_therapy_for_angelman\/","citation_ids":[2453909],"posted_on":"2014-08-29T10:58:32+00:00","author":{"name":"isosafrole","url":"http:\/\/www.reddit.com\/r\/pharmacology","id_on_source":"pharmacology","followers":1513,"subreddit":"pharmacology"}}],"blogs":[{"title":"Could intellectual disability in Angelman syndrome be cured? (Behind the headlines of the lemonade stand girl)","url":"http:\/\/biologybizarre.blogspot.com\/2015\/01\/could-intellectual-disability-in.html","license":"public","citation_ids":[2453909,2939479,136443,3039141],"posted_on":"2015-01-06T03:42:00+00:00","summary":"That it might be possible to improve intellectual ability in Angelman Syndrome individuals was the real news behind the headline last summer about the girl in Toronto with a lemonade stand raising money to cure her brother's disease. Recently&nbsp;Nature p","author":{"name":"BiologyBizarre","url":"http:\/\/biologybizarre.blogspot.com\/","description":"Sharing enthusiasm for the beautiful, the bizarre, the clever and the unexpected in biology"}}],"wikipedia":[{"title":"Topotecan","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=717494896#altmetric_citation_54520857-1271-4439-9845-9b9d7e5b9218","license":"public","citation_ids":[2453909,2453909,2453909],"posted_on":"2016-04-28T01:58:42+00:00","summary":"Topotecan (trade name Hycamtin) is a chemotherapeutic agent that is a topoisomerase inhibitor.","page_url":"http:\/\/en.wikipedia.org\/?curid=4497996","wiki_lang":"en","author":{"name":"Lfstevens","url":"http:\/\/en.wikipedia.org\/wiki\/User:Lfstevens"}}]}}